Medizinisches Laboratorium med. Bernhard Thiele Im Institut für Immunologie und Genetik
Official name: Medizinisches Laboratorium Dr. med. Bernhard Thiele Im Institut für Immunologie und Genetik
170 capabilities
Accredited since January 2025
Verified Apr 2026
One of 3,039 in Germany
Details
Pfaffplatz 10
Kaiserslautern 67655 , Germany
Kaiserslautern 67655 , Germany
Accreditation
Active
DAkkS
D-ML-13374-01-00
Specialises in human genetic testing combining molecular and cytogenetic analysis with virology and transfusion medicine services. Employs PCR-based large-amplicon sequencing and next-generation sequencing technologies on blood and DNA specimens for molecular genetic investigations.
Accreditation Details
Accreditation Body
DAkkS
Number
D-ML-13374-01-00
Status
ActiveSince
29 January 2025
Accreditation is granted under EU Regulation 765/2008 and assessed against ISO/IEC 17025. Data sourced from official DAkkS records.
Download Scope PDFSend an Enquiry
Request a quote, ask about capacity, or discuss your testing requirements directly with this lab.
Test Capabilities (170)
| Standard Reference | Description | Category |
|---|---|---|
| (Customized Panel ABA) | (Customized Panel ABA) | Biocompatibility (ISO 10993) |
| (PROC-Gen [OMIM *612283]) | (PROC-Gen [OMIM *612283]) | Biocompatibility (ISO 10993) |
| (PROS1-Gen [OMIM *1768801) | (PROS1-Gen [OMIM *1768801) | Biocompatibility (ISO 10993) |
| (SERPINC1-Gen [OMIM *107300]) | (SERPINC1-Gen [OMIM *107300]) | Biocompatibility (ISO 10993) |
| (UGT1A1*28-, *6- Polymorphismus) | (UGT1A1*28-, *6- Polymorphismus) | Biocompatibility (ISO 10993) |
| (VWF-Gen [OMIM *613160]) | (VWF-Gen [OMIM *613160]) | Biocompatibility (ISO 10993) |
| 32 Deletion | 32 Deletion | Biocompatibility (ISO 10993) |
| 5-Fluorouracil-Toxizitäts-Panel | 5-Fluorouracil-Toxizitäts-Panel | Biocompatibility (ISO 10993) |
| AF4/MLL-Translokation t(4;11) | AF4/MLL-Translokation t(4;11) | Biocompatibility (ISO 10993) |
| Angeborener Chromosomensatz | angeborener Chromosomensatz | Biocompatibility (ISO 10993) |
| CCND1/IGH-Translokation | CCND1/IGH-Translokation | Biocompatibility (ISO 10993) |
| Chemokinrezeptor 5 (CCR5)-delta | Chemokinrezeptor 5 (CCR5)-delta | Biocompatibility (ISO 10993) |
| Erworbener Chromosomensatz | erworbener Chromosomensatz | Biocompatibility (ISO 10993) |
| FIP1L1-PDGFRA-Fusion | FIP1L1-PDGFRA-Fusion | Biocompatibility (ISO 10993) |
| FSAP [OMIM*603924] dbSNP | FSAP [OMIM*603924] dbSNP | Biocompatibility (ISO 10993) |
| H Bs-Antigen | HBs-Antigen | Biocompatibility (ISO 10993) |
| HLA-Antikörper (Spezifizierung) | HLA-Antikörper (Spezifizierung) | Biocompatibility (ISO 10993) |
| IGH/BCL2-Translokation | IGH/BCL2-Translokation | Biocompatibility (ISO 10993) |
| Nachweis spezifischer chromosomaler | Nachweis spezifischer chromosomaler | Biocompatibility (ISO 10993) |
| RH-System | Rh-System | Biocompatibility (ISO 10993) |
| Thrombophilie-Panel | Thrombophilie-Panel | Biocompatibility (ISO 10993) |
| cABL/BCR-Translokation | cABL/BCR-Translokation | Biocompatibility (ISO 10993) |
| del(4)(q12q12) | del(4)(q12q12) | Biocompatibility (ISO 10993) |
| r5121909548; F2 [OMIM *176930] | r5121909548; F2 [OMIM *176930] | Biocompatibility (ISO 10993) |
| r57080536; MTHFR [OMIM*607093] | r57080536; MTHFR [OMIM*607093] | Biocompatibility (ISO 10993) |
| t(11;14) | t(11;14) | Biocompatibility (ISO 10993) |
| t(9;22), qualitativ | t(9;22), qualitativ | Biocompatibility (ISO 10993) |
| t(9;22), quantitativ | t(9;22), quantitativ | Biocompatibility (ISO 10993) |
| (Zweifeld-Typisierung) | (Zweifeld-Typisierung) | Elemental Analysis |
| DPA1*, DPB1* | DPA1*, DPB1* | Elemental Analysis |
| DRB1*, DQA1*, DQB1* | DRB1*, DQA1*, DQB1* | Elemental Analysis |
| HLA-A*, B*, C* | HLA-A*, B*, C* | Elemental Analysis |
| Anti HBe | Anti-HBe | Food Safety Testing |
| Anti HCV | Anti-HCV | Food Safety Testing |
| Anti-HAV IgG | Anti-HAV-IgG | Food Safety Testing |
| CMV DNA | CMV-DNA | Food Safety Testing |
| EBV EBNA-1 IgG | EBV Ebna-1-IgG | Food Safety Testing |
| HBV DNA | HBV-DNA | Food Safety Testing |
| HCV RNA | HCV-RNA | Food Safety Testing |
| HIV RNA | HIV-RNA | Food Safety Testing |
| ABO System | ABO-System | Immunology / Serology |
| Anti HBC -IgG | Anti HBC -IgG | Immunology / Serology |
| CMV IgG + IgM Antikörper | CMV IgG + IgM Antikörper | Immunology / Serology |
| H1V1/2 Antikörper / p24-Antigen | H1V1/2 Antikörper / p24-Antigen | Immunology / Serology |
| HIV-Wirtsresistenz | HIV-Wirtsresistenz | Immunology / Serology |
| HLA-Antikörper (Crossmatch) | HLA-Antikörper (Crossmatch) | Immunology / Serology |
| HTLV1/11 Antikörper | HTLV1/11 Antikörper | Immunology / Serology |
| Kell-Antigen | Kell-Antigen | Immunology / Serology |
| Rubella-Virus IgG Antikörper | Rubella-Virus IgG Antikörper | Immunology / Serology |
| anti-HBs quantitativ | anti-HBs quantitativ | Immunology / Serology |
| freie irreguläre Antikörper | freie irreguläre Antikörper | Immunology / Serology |
| (CFTR-Gen [OMIM *6024211) | (CFTR-Gen [OMIM *6024211) | Molecular Diagnostics / PCR |
| (FBN1-Gen [OMIM *134797]) | (FBN1-Gen [OMIM *134797]) | Molecular Diagnostics / PCR |
| (Gen-Panel mit 978 Genen) | (Gen-Panel mit 978 Genen) | Molecular Diagnostics / PCR |
| (TP 53-Gen) | (TP 53-Gen) | Molecular Diagnostics / PCR |
| (in-house) | (in-house) | Molecular Diagnostics / PCR |
| *134820], GSN [OMIM *137350], LYZ [OMIM *1534501, OSMR [OMIM | *134820], GSN [OMIM *137350], LYZ [OMIM *1534501, OSMR [OMIM | Molecular Diagnostics / PCR |
| *136351], IDH1 [OMIM *1477001, IDH2 [OMIM *1476501, JAK2 [OMIM | *136351], IDH1 [OMIM *1477001, IDH2 [OMIM *1476501, JAK2 [OMIM | Molecular Diagnostics / PCR |
| *1389711, DDX41 [OMIM *6081701 | *1389711, DDX41 [OMIM *6081701 | Molecular Diagnostics / PCR |
| *1477961, KIT [OMIM *164920], NPM1 [OMIM *164040], NRAS | *1477961, KIT [OMIM *164920], NPM1 [OMIM *164040], NRAS | Molecular Diagnostics / PCR |
| *1513851, SETBP1 [OMIM *6110601, SF3B1 [OMIM *605590], SRSF2 | *1513851, SETBP1 [OMIM *6110601, SF3B1 [OMIM *605590], SRSF2 | Molecular Diagnostics / PCR |
| *1607101, MYH7 [OMIM *160760], NXN [OMIM *612895], PLN [OMIM | *1607101, MYH7 [OMIM *160760], NXN [OMIM *612895], PLN [OMIM | Molecular Diagnostics / PCR |
| *172405], PRDM16 [OMIM | *172405], PRDM16 [OMIM | Molecular Diagnostics / PCR |
| *300377], DSG2 [OMIM *125671], DSP [OMIM *1256471, EMD [OMIM | *300377], DSG2 [OMIM *125671], DSP [OMIM *1256471, EMD [OMIM | Molecular Diagnostics / PCR |
| *3003841, EYA4 [OMIM *603550], FHL1 [OMIM *300163], HFE [OMIM | *3003841, EYA4 [OMIM *603550], FHL1 [OMIM *300163], HFE [OMIM | Molecular Diagnostics / PCR |
| *600163], SGCD [OMIM *601411], TAZ [OMIM *300394], TCAP [OMIM | *600163], SGCD [OMIM *601411], TAZ [OMIM *300394], TCAP [OMIM | Molecular Diagnostics / PCR |
| *6044881, TMPO [OMIM *1883801, TNNI3 [OMIM *1910441, TNNT2 | *6044881, TMPO [OMIM *1883801, TNNI3 [OMIM *1910441, TNNT2 | Molecular Diagnostics / PCR |
| *605557], PSEN1 [OMIM *1043111, PSEN2 [OMIM *600759], RBM20 | *605557], PSEN1 [OMIM *1043111, PSEN2 [OMIM *600759], RBM20 | Molecular Diagnostics / PCR |
| *6095991, BAG3 [OMIM *6038831 | *6095991, BAG3 [OMIM *6038831 | Molecular Diagnostics / PCR |
| *6128391, TP53 [OMIM *1911701, U2AF1 [OMIM *1913171, ZRSR2 | *6128391, TP53 [OMIM *1911701, U2AF1 [OMIM *1913171, ZRSR2 | Molecular Diagnostics / PCR |
| *6136091 , LDB3 [OMIM *605906], LMNA [OMIM *150330], MYBPC3 | *6136091 , LDB3 [OMIM *605906], LMNA [OMIM *150330], MYBPC3 | Molecular Diagnostics / PCR |
| Amyloidose | Amyloidose | Molecular Diagnostics / PCR |
| Antithrombin-III-Mangel | Antithrombin-III-Mangel | Molecular Diagnostics / PCR |
| CNV | FMR1 [OMIM*309550], AFF2 [OMIM*300806]; SNV, CNV | Molecular Diagnostics / PCR |
| CSRP3 [OMIM *6008241 , DES | CSRP3 [OMIM *6008241 , DES | Molecular Diagnostics / PCR |
| Chimärismusanalyse | Chimärismusanalyse | Molecular Diagnostics / PCR |
| DNMT3A [OMIM *6027691 , EZH2 | DNMT3A [OMIM *6027691 , EZH2 | Molecular Diagnostics / PCR |
| Dilatative Kardiomyopathie (DCM) | Dilatative Kardiomyopathie (DCM) | Molecular Diagnostics / PCR |
| Entwicklungsstörungen | Entwicklungsstörungen | Molecular Diagnostics / PCR |
| Exomsequenzierung (SNV, CNV) | Exomsequenzierung (SNV, CNV) | Molecular Diagnostics / PCR |
| Familienanamnese. | Familienanamnese. | Molecular Diagnostics / PCR |
| HIV-RNA oder provirale DNA | HIV-RNA oder provirale DNA | Molecular Diagnostics / PCR |
| HNPCC/Lynch-Syndrom | HNPCC/Lynch-Syndrom | Molecular Diagnostics / PCR |
| HPV DNA | HPV-DNA | Molecular Diagnostics / PCR |
| Hereditäres Pankreaskarzinom | Hereditäres Pankreaskarzinom | Molecular Diagnostics / PCR |
| Mammakarzinom, metastasiertes | Mammakarzinom, metastasiertes | Molecular Diagnostics / PCR |
| Marfan Syndrom | Marfan-Syndrom: FBN1, TGFBR1, TGFBR2, ACTA2, COL3A1, MYH11, MYLK, SMAD3, TGFB2 | Molecular Diagnostics / PCR |
| Meulengracht- (Gilbert)-Syndrom | Meulengracht- (Gilbert)-Syndrom | Molecular Diagnostics / PCR |
| Myelodysplastisches Syndrom | Myelodysplastisches Syndrom | Molecular Diagnostics / PCR |
| Nachweis spezifischer | Nachweis spezifischer | Molecular Diagnostics / PCR |
| OMIM*612839, TP53 | OMIM*612839, TP53 | Molecular Diagnostics / PCR |
| Ovarialkarzinom (HBOC) | Ovarialkarzinom (HBOC) | Molecular Diagnostics / PCR |
| Pankreaskarzinom nach | Pankreaskarzinom nach | Molecular Diagnostics / PCR |
| Prostatakarzinom zur | Prostatakarzinom zur | Molecular Diagnostics / PCR |
| Protein C-Mangel | Protein-C-Mangel | Molecular Diagnostics / PCR |
| Protein S-Mangel | Protein-S-Mangel | Molecular Diagnostics / PCR |
| Risiko nach positiver | Risiko nach positiver | Molecular Diagnostics / PCR |
| Ungerichtete NGS-basierende | Ungerichtete NGS-basierende | Molecular Diagnostics / PCR |
| Vermutetes erhöhtes hereditäres | Vermutetes erhöhtes hereditäres | Molecular Diagnostics / PCR |
| Zystische Fibrose | Zystische Fibrose | Molecular Diagnostics / PCR |
| [OMIM *102573], ANKRD1 [OMIM | [OMIM *102573], ANKRD1 [OMIM | Molecular Diagnostics / PCR |
| [OMIM *109700], FGA [OMIM | [OMIM *109700], FGA [OMIM | Molecular Diagnostics / PCR |
| [OMIM *125660], DMD [OMIM | [OMIM *125660], DMD [OMIM | Molecular Diagnostics / PCR |
| [OMIM *164790], RUNX1 [OMIM | [OMIM *164790], RUNX1 [OMIM | Molecular Diagnostics / PCR |
| [OMIM *165360], CSF3R [OMIM | [OMIM *165360], CSF3R [OMIM | Molecular Diagnostics / PCR |
| [OMIM *191045], TPM1 [OMIM | [OMIM *191045], TPM1 [OMIM | Molecular Diagnostics / PCR |
| [OMIM *6008131, TET2 [OMIM | [OMIM *6008131, TET2 [OMIM | Molecular Diagnostics / PCR |
| [OMIM *600958], MYH6 [OMIM | [OMIM *600958], MYH6 [OMIM | Molecular Diagnostics / PCR |
| [OMIM *6015731, FLT3 [OMIM | [OMIM *6015731, FLT3 [OMIM | Molecular Diagnostics / PCR |
| [OMIM *613171], SCN5A [OMIM | [OMIM *613171], SCN5A [OMIM | Molecular Diagnostics / PCR |
| chromosomaler Regionen | chromosomaler Regionen | Molecular Diagnostics / PCR |
| metastasierendes Mammakarzinom | metastasierendes Mammakarzinom | Molecular Diagnostics / PCR |
| t(14;18) | t(14;18) | Molecular Diagnostics / PCR |
| t(15;17) | t(15;17) | Molecular Diagnostics / PCR |
| t(1;19) | t(1;19) | Molecular Diagnostics / PCR |
| t(8;21) | t(8;21) | Molecular Diagnostics / PCR |
| (ACTC1 [OMIM *1025401, ACTN2 | (ACTC1 [OMIM *1025401, ACTN2 | Other |
| (AP0A1 [OMIM *1076801, B2M | (AP0A1 [OMIM *1076801, B2M | Other |
| (ASXL1 [OMIM *612990], CBL | (ASXL1 [OMIM *612990], CBL | Other |
| (AT3 [OMIM *1073001 dbSNP | (AT3 [OMIM *1073001 dbSNP | Other |
| (DPYD (OMIM *612779), dbSNP | (DPYD (OMIM *612779), dbSNP | Other |
| (Detektion von 55 Mutationen | (Detektion von 55 Mutationen | Other |
| (MDS) | (MDS) | Other |
| *1910101 , TTN [OMIM *188840], VCL [OMIM *1930651) | *1910101 , TTN [OMIM *188840], VCL [OMIM *1930651) | Other |
| *6006781 , PMS2 [OMIM *6002591, EPCAM [OMIM *1855351) | *6006781 , PMS2 [OMIM *6002591, EPCAM [OMIM *1855351) | Other |
| *6006781, PMS2 [OMIM *600259], EPCAM [OMIM *1855351) | *6006781, PMS2 [OMIM *600259], EPCAM [OMIM *1855351) | Other |
| *601743], TTR [OMIM *176300]) | *601743], TTR [OMIM *176300]) | Other |
| *6029541, STK11 [OMIM *6022161, TP53 [OMIM *1911701) | *6029541, STK11 [OMIM *6022161, TP53 [OMIM *1911701) | Other |
| AKS | AKS | Other |
| HLA-Antikörper (Nachweis | HLA-Antikörper (Nachweis | Other |
| Inhibitoren) | Inhibitoren) | Other |
| SNV-Genotypisierung (Nachweis | SNV-Genotypisierung (Nachweis | Other |
| [OMIM *300028]) | [OMIM *300028]) | Other |
| [OMIM *6001851) | [OMIM *6001851) | Other |
| [OMIM *602421]) | [OMIM *602421]) | Other |
| [OMIM*173360] dbSNP r52227631, rs587776796) | [OMIM*173360] dbSNP r52227631, rs587776796) | Other |
| den Genen DNMT3A, FLT3, IDH1, IDH2, KIT, and NPM1) | den Genen DNMT3A, FLT3, IDH1, IDH2, KIT, and NPM1) | Other |
| lnhibitoren) | lnhibitoren) | Other |
| r53918290, rs55886062, rs56038477, rs67376798, rs72549309 und rs75017182) | r53918290, rs55886062, rs56038477, rs67376798, rs72549309 und rs75017182) | Other |
| (BRCA1 [OMIM *1137051, BRCA2 | (BRCA1 [OMIM *1137051, BRCA2 | Spectroscopy (XRF, ICP, AAS) |
| (FBN1-Gen [OMIM *1347971) | (FBN1-Gen [OMIM *1347971) | Spectroscopy (XRF, ICP, AAS) |
| (MLH1 [OMIM *120436] , MSH2 | (MLH1 [OMIM *120436] , MSH2 | Spectroscopy (XRF, ICP, AAS) |
| (PROC-Gen [OMIM *6122831) | (PROC-Gen [OMIM *6122831) | Spectroscopy (XRF, ICP, AAS) |
| (VWF-Gen [OMIM *6131601) | (VWF-Gen [OMIM *6131601) | Spectroscopy (XRF, ICP, AAS) |
| *6058821, CDH1 [OMIM *1920901 | *6058821, CDH1 [OMIM *1920901 | Spectroscopy (XRF, ICP, AAS) |
| *6093091, MSH6 [OMIM *600678], PMS2 [OMIM *6002591 , PTEN | *6093091, MSH6 [OMIM *600678], PMS2 [OMIM *6002591 , PTEN | Spectroscopy (XRF, ICP, AAS) |
| +604373], PALB2 [OMIM *6103551, RAD51C [OMIM *6027741, ATM | +604373], PALB2 [OMIM *6103551, RAD51C [OMIM *6027741, ATM | Spectroscopy (XRF, ICP, AAS) |
| 1. Rezidiv eines Ovarialkarzinoms | 1. Rezidiv eines Ovarialkarzinoms | Spectroscopy (XRF, ICP, AAS) |
| 2. HER2-negatives primäres | 2. HER2-negatives primäres | Spectroscopy (XRF, ICP, AAS) |
| EPCAM [OMIM *1855351, MLH1 | EPCAM [OMIM *1855351, MLH1 | Spectroscopy (XRF, ICP, AAS) |
| Fragmentlängen-Analyse | Fragmentlängen-Analyse | Spectroscopy (XRF, ICP, AAS) |
| Gerichtete NGS-Panel-Analyse | Gerichtete NGS-Panel-Analyse | Spectroscopy (XRF, ICP, AAS) |
| Gezielte Kopienzahlanalyse | Gezielte Kopienzahlanalyse | Spectroscopy (XRF, ICP, AAS) |
| Hereditäres Mamma-/ | Hereditäres Mamma-/ | Spectroscopy (XRF, ICP, AAS) |
| MYH11/CBFB-Translokation | MYH11/CBFB-Translokation | Spectroscopy (XRF, ICP, AAS) |
| Mamma-/Ovarialkarzinom | Mamma-/Ovarialkarzinom | Spectroscopy (XRF, ICP, AAS) |
| PBX1/E2A-Translokation | PBX1/E2A-Translokation | Spectroscopy (XRF, ICP, AAS) |
| PML/RARA-Translokation | PML/RARA-Translokation | Spectroscopy (XRF, ICP, AAS) |
| RUNX1/RUNX1T1-Translokation | RUNX1/RUNX1T1-Translokation | Spectroscopy (XRF, ICP, AAS) |
| Zystische Fibrose (CFTR-Gen | Zystische Fibrose (CFTR-Gen | Spectroscopy (XRF, ICP, AAS) |
| [OMIM *1204361, MSH2 [OMIM | [OMIM *1204361, MSH2 [OMIM | Spectroscopy (XRF, ICP, AAS) |
| [OMIM *6001851 , CHEK2 [OMIM | [OMIM *6001851 , CHEK2 [OMIM | Spectroscopy (XRF, ICP, AAS) |
| [OMIM *6017281, RAD51D [OMIM | [OMIM *6017281, RAD51D [OMIM | Spectroscopy (XRF, ICP, AAS) |
| [OMIM *6075851, BRIP1 [OMIM | [OMIM *6075851, BRIP1 [OMIM | Spectroscopy (XRF, ICP, AAS) |
| [OMIM *6093091 , MSH6 [OMIM | [OMIM *6093091 , MSH6 [OMIM | Spectroscopy (XRF, ICP, AAS) |
| [OMIM *609309], MSH6 [OMIM | [OMIM *609309], MSH6 [OMIM | Spectroscopy (XRF, ICP, AAS) |
| fortgeschrittenes Ovarialkarzinom, metastasiertes und HER2-negatives | fortgeschrittenes Ovarialkarzinom, metastasiertes und HER2-negatives | Spectroscopy (XRF, ICP, AAS) |
| EBV - VCA - IgG | EBV VCA IgG | Sterility Testing |
| EBV - VCA - IgM | EBV VCA IgM | Sterility Testing |
| inv(16) | t(15;17), BFB/MYH 11inv(16) | Sterility Testing |